Company history

Minerva Analytix GmbH (German equivalent of an Inc.) was founded in 1999 as part of Minerva Biolabs GmbH by Dr. Dirk Vollenbroich. Analytic services were part of the company right from the beginning.

As a result of continuing growth in a GMP regulated environment the two divisions Minerva Analytix GmbH and Minerva Biolabs GmbH were separated in 2014. While Minerva Biolabs GmbH continues to produce high quality products in the field of contamination safety, Minerva Anlytix GmbH now has its own facilities and thus fulfills an important criterion for GMP-compliant test laboratories.

With the 2017 re-certification we have successfully finished rebuilding the quality management system according to EU-GMP and cGMP guidelines and extended the scope of our testing by endotoxin testing.

Our BSL-2/3 **, Genetic Engineering S2 and Infection Protection permits have been renewed.

We have successfully established Vector Copy Number Testing for R&D and in-process control and are preparing to implement it as a GMP-compliant testing service for batch release. This method enables precise quantification of genetic material within 24–48 hours, offering a fast and reliable alternative to traditional approaches.

Our new facilities are finished – all required inspections (GMP, Biosafety, Work Safety and Genetic Engineering) have been positively been renewed. We are ready to start at our new Rangsdorf site close to Berlin and are looking forward to working with you.

We are happy to grow together with our customers and are able to move into a renovated new floor with office space. Despite the difficult situation in the Covid-19 year, we continue to be available for our GMP customers and plan to expand our service capacity in the field of rapid microbial testing by nucleic acid amplification.

In 2024, we joined an international pharmaceutical network, enabling us to strengthen our financial foundation and prepare for future portfolio expansion. As part of a broader Pharma QC structure, we are well-positioned to support our clients with enhanced capabilities and regulatory expertise. We warmly welcome long-standing partners to reconnect and look forward to new collaborations in the evolving landscape of pharmaceutical analytics.